| Name | Title | Contact Details |
|---|
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
Protalix BioTherapeutics , Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
The RADIANCE-HTN Clinical study is a randomized, controlled study to evaluate the Paradise Renal Denervation System intended to treat high blood pressure. The study will be in up to 40 hospitals in 5 countries (US, France, Germany, The Netherlands, UK...
Encounter Telehealth supports the mental and behavioral health needs of residents in senior living communities across the country. #mentalhealth #telehealth
Fusion MD Network is a Montreal, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.